As previously mentioned, the cyclic peptide inhibitor of C3, pegcetacoplan, was approved by the FDA in May 2021 for the treatment of adult patients with PNH (58), thereby further expanding the list of approved treatment options that target the complement system. This evidence concerns the gene C3 and paroxysmal nocturnal hemoglobinuria.